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Summary 
The class II transactivator (CIITA) and B cell octamer-binding protein 1/octamer-binding fac- 
tor 1/Oct coactivator from B cells (Bobl/OBF-1/OCA-B) represent two B cell--specific tran- 
scriptional coactivators.  CIITA and Bobl  interact with proteins that bind  to conserved up- 
stream sequences in promoters of class II major histocompatibility genes and octamer-binding 
transcription factors Oct-1 and Oct-2, respectively. Both CIITA and Bobl increase the expres- 
sion from the DtLA promoter, which is a prototypic class II promoter. Moreover, in the pres- 
ence of CIITA, interactions between class II promoters and Bobl  are independent of the oc- 
tamer-binding site. Using in vivo and in vitro binding assays, we confirm that Bobl binds to 
CIITA. Thus, CIITA not only activates the expression of class II genes but recruits another B 
cell--specific coactivator to increase transcriptional activity of class II promoters in B cells. 
T 
ranscription of MHC  class II genes  (class II) is regu- 
lated  by  promoter  elements,  which  consist  of con- 
served upstream sequences  (CUS)  called the  S,  X,  and Y 
boxes and downstream sequences, which in the DRA pro- 
moter, include an octamer-binding site (OBS) 1 (see Fig. 1) 
(for reviews see references  1-5). Whereas the B  cell-spe- 
cific and IFN-~/-inducible expression depend absolutely on 
the X  box (6), these other promoter sequences are also re- 
quired for optimal levels of class II transcription (7). More- 
over, mutations in proteins, which interact with the X box, 
result in  a  severe combined immunodeficiency called the 
type II bare lymphocyte syndrome  (BLSII) (1,  8).  Genes 
mutated  in  two  of the  four  complementation  groups  of 
BLSII have been isolated (9,  10).  Of these,  the regulatory 
factor X5  (RFX5)  is  a  component  of the  RFX  hetero- 
dimer, which binds to the X box (10).  In contrast, the class 
II transactivator  (CIITA) does not bind directly to DNA 
(9).  CIITA is expressed at high levels in B  cells  and acti- 
vated T  cells but is also induced by IFN-~ and mediates ef- 
fects of IFN-~/ on the  expression of class II in APCs  (11, 
12).  Moreover, the absence of CIITA has been correlated 
with the extinction of class II on plasma cells (13). 
Recently, the gene coding for the coactivator involved 
in the B  cell-specific transcription of Ig genes was identi- 
fied (10,  11).  B  cell octamer-binding protein  1/octamer- 
binding factor 1/Oct coactivator from B cells (Bobl/OBF- 
1Abbreviations used in this paper: Bobl, B cell octamer-binding  protein 1; 
CIITA, Class II wansactivator;  OBS, octamer-binding  site. 
1/OCA-B; hereafter Bobl) binds to Oct-1 and Oct-2 and 
increases  their  ability  to  activate  transcription  in  B  cells 
(14-16).  Since the DRA promoter contains an OBS,  we 
wondered if Bob1 also regulates its expression. Indeed, Bob1 
activated the DRA promoter and acted synergistically with 
CIITA. Using the DQ~ promoter, which does not contain 
an OBS, and a DRA promoter bearing clustered point mu- 
tations in the OBS, we also demonstrated that this syner- 
gism was  independent  of the  OBS.  Furthermore,  Bob1 
bound to CIITA in vivo and in vitro, which explains their 
cooperative interactions  in  activating the  transcription  of 
class II genes. 
Materials and Methods 
Cell Culture, Transfection, arm CA T Assay.  Jurkat ceRs were grown 
in RPMI containing  10% FCS and antibiotics,  under 5% CO2. 
Transfections were performed by electroporation  (960 mF, 250 V) 
using 107 cells in 0.4 ml RPMI. Unless otherwise stated, the total 
amount of DNA was kept constant at 40 ~g. Specific amounts of 
DNA for each transfection are noted in the figure legends. 48 h 
at~er transfection, cells were harvested, and CAT enzymatic assays 
were performed as described (17). 
In Vitro Protein Binding Assays.  Glutathione-S-transferase  (GST) 
CIITA fusion protein was produced using the baculovirus Bacu- 
loGold expression  system  from PharMingen  (San Diego,  CA). 
GST protein was produced in bacteria, from the plasmid pGEX2tk 
(Promega Corp., Madison, WI), as described (18). Equal amounts 
of GST or GSTCIITA were bound to glutathione--sepharose beads 
(Pharmacia,  Uppsala,  Sweden)  in EBC-D buffer (50 mM Tris- 
HC1, pH 8.0,  120 mM NaCI, 0.5% NP-40, and 5 mM dithio- 
threitol),  washed  several  times  in  EBC-D  containing  0.075% 
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of [3sSl-methionine  labeled Bob1  which was transcribed/trans- 
lated in vitro (TNT Coupled transcription/translation  kit;  Pro- 
mega, Corp.)  was added. The binding reaction was mixed for 1 h 
at 4~  and washed four times in EBC-D, where the concentra- 
tion of NaC1 was increased to 250 raM. The Sepharose pellet was 
resuspended in 25 ~1 of SDS-loading  buffer, boiled  for 10 min, 
and  loaded  onto  a  8%  SDS-polyacrylamide  gel. After  electro- 
phoresis,  the  gel was dried  and  autoradiographed  overnight on 
ECL Hyperfilm (Amersham Corp., Arlington Heights, IL). 
Results 
Since the DtkA promoter contains an OBS, we wanted 
to determine if Bob1 could regulate its levels of expression. 
Jurkat T cells were chosen because they express neither Bob1 
nor CIITA (Fontes, J.D.,  and B.M.  Peterlin,  unpublished 
data),  pDRASCAT,  which  contains  the  DRA  promoter 
linked to the CAT reporter gene (Fig.  1 A)  (7), was trans- 
fected  alone  and  with  increasing  amounts  of pCBOB1 
which directs the expression of Bob1, into Jurkat cells. Ex- 
pression  from  pDRASCAT  increased  with  increasing 
amounts ofpCBOB1  (Fig 1 B). At the maximum concen- 
trations  of pCBOB1,  CAT  levels were  ool0-fold  greater 
than  those  observed with pDRASCAT  alone.  This  result 
indicates that Bob1 interacts with proteins that bind to the 
OBS, and activates transcription from the DRA promoter 
in the absence of CIITA. 
We next examined the ability of Bob1  to activate tran- 
scription from the DRA promoter in the presence of CIITA. 
Cotransfections of pCCIITA (Fig.  1 A) with pDR_ASCAT 
(the ratio of the plasmid effector to target was 1:1) resulted 
in 12-fold higher CAT activities (Fig.  t  C). At the same ra- 
tio  of the  plasmid  effector  and  target,  the  expression  of 
Bob1  resulted in twofold higher CAT activities (Fig.  1,  B 
and  C).  However,  when  both  pCCIITA  and  pCBOB1 
were  cotransfected with pDRASCAT,  CAT activities in- 
creased 40-fold  (Fig.  1  C).  This level of activation repre- 
sents greater than additive effects between Bob1 and CIITA 
on the DRA promoter. 
Of all class II promoters, only the DRA promoter con- 
tains an OBS. Thus, to determine if Bob1 could also activate 
other class II promoters alone or with CIITA, we used the 
DQ[3 promoter, which contains S, X, and Y boxes but lacks 
the OBS  (19).  pDQbAT  (Fig.  2 A) was transfected alone, 
with pCBOB1 and with pCBOB1 and pCCIITA into Jurkat 
cells. CIITA activated the DQ[3 promoter sixfold (Fig. 2 B). 
As  expected,  Bob1  had no  effect on the  expression from 
pDQbCAT.  However, when pCBOB1  was cotransfected 
with  pCCIITA, CAT levels increased more than  15-fold 
(Fig.  2  B).  Although  these levels were shghtly lower than 
those  observed with  the  DRA  promoter,  they  represent 
synergistic activation of the DQ[3 promoter by Bob1  and 
CIITA. That these synergistic activities between CIITA and 
Bob1  were indeed  independent  of the  OBS was  also  re- 
vealed by another plasmid target, pDRASM11CAT, which 
contains clustered point mutations in the OBS of the DRA 
promoter (Fig.  2  A)  (7).  Fig.  2  B  demonstrates that Bob1 
alone could not increase expression from pDRASM11CAT. 
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Figure  1.  Bobl  activates the DtLA promoter, alone and synergistically 
with CIITA in Jurkat cells. (A) Plasmid effectors pCCIITA and pCBOB 1 
direct the expression of their respective cDNAs from the CMV promoter. 
The  plasmid target  pDILASCAT was described previously (7).  (B)  In- 
creasing amounts ofpCBOB1  (0,  10, 30, and 50 p~g) were co-transfected 
with a constant amount of pDRASCAT (10 p~g) into Jurkat cells.  In the 
absence of pCBOB1,  the activity of the DRA  promoter was set to  1. 
Bob1  led up to  10-fold-higher levels of expression from the DRA pro- 
moter. (C) pCCIITA (10 p,g) and pCBOB1  (10 ixg) alone increased ex- 
pression ofpDtLASCAT (10 b~g) 12- and 2.1-fold, respectively. Cotrans- 
fections  of both  pCCIITA  and  pCBOB1  (10  /a,g each)  resulted  in 
synergistically increased  (40-fold)  expression from the DRA promoter. 
(HA)  Influenza hemagglutinin tag,  (S, X,  Y, and O)  OBS,  (lnr)  initiator 
sequences from the DRA promoter, (pCR3) parental plasmid for pCCIITA 
and pCBOB1, and (Fold TA)  fold transactivation, pCR3 was also added 
to keep total amounts ofcotransfected plasmids constant. Plasmid effectors 
are given to the left of and plasmid targets inside the bar graphs. To the 
right of each bar graph are schematic representations of protein-protein 
interactions between coactivators and proteins, which bind to cis-acting 
sequences in  class  II  promoters.  Shown  are  representative experiments 
from three transfections done in duplicate.  Standard errors  of the mean 
were <10%. 
However, CIITA increased the expression from this plasmid 
almost 9-fold, and together with Bob1, levels of expression 
from pDRASMllCAT increased more than 17-fold. Again, 
this increase represents greater than multiplicative effects of 
Bob1  and CIITA on the mutated DRA promoter that lacks 
the OBS. 
That Bob1  and CIITA could also activate synergistically 
the expression from class II promoters lacking the OBS led 
to the possibility that the two coactivators were interacting 
directly. To test this hypothesis we used an in vivo binding 
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Figure  2.  Bob1  and  CIITA  act 
synergistically on  class II  promoters 
even  in  the  absence  of the  OBS. 
pDQbCAT  contained the promoter 
of the DQ[3 gene, which is a class II 
promoter that lacks an OBS  (Fontes 
and Peterlin, unpublished data).  In- 
stead of the OBS (O), DQ[3 contains 
a  CCAA  sequence  (C).  pDRA- 
SMllCAT  contains clustered point 
mutations  in  the OBS  of pDRAS- 
CAT  (7).  Alone and together, pC- 
CIITA  and pCBOB1  were cotrans- 
fected  with  the  indicated  plasmid 
targets.  Amounts  of DNA  were  as 
follows: 5  I-~g  of pDQbCAT, 20 ~g 
of  pCCIITA,  and  20  ~g  of 
pCBOB1;  5  ~g  of  pDRA- 
SM11CAT, 10 ~g ofpCCIITA, and 
20  ~g  of  pCBOB1,  pCR.3  was 
added  to  keep  total  amounts  of 
cotransfected  plasmids  constant. 
Plasmid effectors are given to the left 
of and plasmid targets inside the bar 
graphs.  (White and  striped boxes) 
Cotransfections  with  pDQbCAT 
and pDRASM11CAT,  respectively. 
Shown  are  representative  experi- 
ments from three transfections done 
in  duplicate.  Standard errors of the 
mean were < 10%. 
assay. The DNA-binding domain of Gal4  (DNABD)  was 
linked to  the  full-length  CIITA  (pSGCIITA)  (Fig.  3  A). 
Two plasmid targets were used. The first plasmid contains 
the binding site for Gal4 (UASg) upstream of the OBS, pu- 
tative  TATA  sequence  and  initiator  (Inr)  from the  DRA 
promoter (pDRASUASgCAT)  (Fig. 3 A) (20). The second 
plasmid contains a single UASg upstream of the TATA box 
from the Elb promoter ofadenovirus (pGIElbCAT)  (Fig. 
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Figure  3.  Bob1  interacts  di- 
rectly  with  CIITA  to  produce 
transcriptional synergy.  (A)  The 
plasmid  effector  (pSGCIITA) 
contains the Gal4 DNA-binding 
domain (DNABD) 5' and linked 
to the full-length CIITA cDNA. 
These plasmid targets  were used: 
pG1ElbCAT  contains one  Gal4 
binding site 5' to the TATA box 
from the Elb promoter ofaden- 
ovirus  (8)  and  pDRASUASg- 
CAT  contains  a  single  Gal4 
DNA binding site (UASg) 5'  to 
the  OBS,  putative  TATA  and 
Inr  sequences  from  the  DRA 
promoter  (19).  (B)  Indicated 
plasmid  effectors were  cotrans- 
fected with and without pCBOB1 
and  pGIElbCAT  or  pDRA- 
SUASgCAT into Jurkat cells. 5 ~g 
of plasmid targets (pG1ElbCAT 
and pDRASUASgCAT),  and  15 
~g ofplasmid effectors (pSG424, 
pSGCIITA, and pCBOB1)  were 
used.  (None,  left) Only  pCR3 
was cotransfected with the plas- 
mid  targets,  pSG424  is  the  pa- 
rental  plasmid  of  pSGCIITA. 
(White and striped boxes) Cotransfections with pG1E 1  bCAT and pDRASUASgCAT, respectively. Plasmid effectors are given to the left of and plasmid 
targets inside the bar graphs. Shown are representative experiments from three transfections done in duplicate. Standard errors of the mean were <10%. 
2519  Fontes et al. 3 A) (8). Using these plasmid targets, the interaction of CI- 
ITA and Bob1 was assessed in the presence and absence of 
the OBS. Both plasmids were activated to well above back- 
ground levels by pSGCIITA. In fact, the  expression from 
pG1ElbCAT  and  pDR.AUASgCAT  was  increased  more 
than 15- and 7-fold, respectively (Fig.  3 B). 
pCBOB1  was also cotransfected with pSG424  (the pa- 
rental vector ofpSGCIITA) and these two plasmid targets. 
Bob1  had no effect on the expression from pGIElbCAT, 
which  does not  contain the  OBS.  As expected, Bob1  in- 
creased  twofold  the  expression pDRAUASgCAT,  which 
contains  the  OBS  (Fig.  3  B).  These  data were  similar to 
those observed with pDRASCAT (Figs. 1 and 2). However, 
results obtained when both pSGCIITA and pCBOB1 were 
cotransfected with these plasmid targets were more significant. 
In cotransfections with pCBOB1 and pSGCIITA, the expres- 
sion from pDRAUASgCAT increased 95-fold (Fig. 3 B). This 
finding was confirmed with pG1ElbCAT, where the same 
plasmid effectors increased the expression from pGIElbCAT 
90-fold. These degrees of activation were more than multi- 
plicative and indicate  that Bob1  and  CIITA interacts  with 
each other in  cells.  In control cotransfections, activation of 
pDRAUASgCAT  and  pGIElbCAT  by  a  fusion  protein 
containing the Gal4 DNABD and the activation domain of 
VP16 from the HSV was not affected by pCBOB1, i.e., Bob1 
did not interact with an irrelevant viral transactivator (19). 
To  confirm  that  Bob1  interacts  with  CIITA,  a  direct 
binding assay was performed with CIITA and Bob1 in vitro. 
A  fusion protein between  GSTCIITA fusion protein was 
incubated  with  Bob1  translated  in  the  rabbit reticulocyte 
lysate. GSTCIITA was purified with glutathione-sepharose 
beads and bound proteins were analyzed by SDS-PAGE fol- 
lowed by autoradiography. Bob1 measured 40 kD  (Fig.  4, 
lane  1). When combined with Bob1, GSTCIITA also pulled 
down a protein of identical molecular weight (Fig.  4, lane 
2). However, when GST alone was incubated with Bob1, 
no Bob1 was detected (Fig. 4, lane 3), indicating that inter- 
actions  between  Bob1  and  CIITA  were  specific.  Thus, 
GSTCIITA and Bob1 bind to each other directly. The de- 
gree of binding between Bob1  and CIITA in our gel was 
similar to  that  observed previously with  Oct-1  and Bob1 
(16,  and Fontes and Peterlin, unpublished data). 
Discussion 
This  report represents the  first demonstration  of direct 
interactions between two transcriptional coactivators. CIITA 
Figure 4.  Bobl and CIITA bind each other in vitro. Lane 1 contains 
the input Bob1, which was translated in the rabbit reticulocyte lysate. 
Lane 2 contains Bob1 which bound to GSTCIITA.  Lane 3 contains Bob1 
which was incubated with GST alone. 
interacts with proteins bound to class II promoters (20) and 
at least one  human  TBP-associated factor (TAF)  (Fontes, 
J.D.,  and  B.M.  Peterlin,  unpublished  data).  Since  Bob1 
contains an activation domain different than that of CIITA 
(21),  the  presence of Bob1  provides an  additional  surface 
for interactions  with  a  second  TAF.  This  scenario  repre- 
sents a variation on the theme of transcriptional synergy re- 
vealed  by  two  Drosophila  transactivators,  bicoid  and 
humpback, which bind to DNA and contact two  distinct 
TAFs (22).  Cooperative interactions with general transcrip- 
tion factors then result in more efficient binding of TFIID 
at the promoter, which leads to higher rates of initiation of 
transcription. 
From this study, it is clear that CIITA is the primary reg- 
ulator of class II transcription and that  effects of Bob1  are 
dictated by CIITA. This observation divorces expression of 
class II from Ig genes in the ontogeny of B  cells,  where Igs 
are expressed before class II determinants appear and after 
their  extinction  in  plasma cells  (23).  Moreover,  the  pres- 
ence of both CIITA and Bob1 leads to the very high levels 
of class II in B  cells,  where they are required for optimal T 
cell help (24).  In sharp contrast, IFN-~/induces the synthe- 
sis  of only  CIITA  in  APCs  (25).  Since  these  cells  lack 
Bob1, levels of class II in APCs are lower than those in B 
cells and reflect only the requirement of class II for optimal 
antigen processing and presentation. 
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